This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to VIP through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription compound.
Some patients do every standard test and get normal results. Their basic inflammation markers look fine, yet they remain symptomatic in ways conventional medicine struggles to explain. A subset of these individuals may have what researchers describe as dysregulated immune signaling — a sustained inflammatory state that persists beyond what standard markers detect. Understanding what regulates that resolution is where vasoactive intestinal peptide enters the picture.
VIP is an endogenous neuropeptide the body uses to regulate immune homeostasis, vascular tone, and mucosal function. Here is how it works, what the research supports, and how to evaluate whether it may be relevant to your clinical situation.
Key Takeaways
- Regulatory Status: Not FDA-approved for any indication in its compounded nasal spray form. The synthetic VIP analog aviptadil received FDA Fast Track Designation for COVID-19 ARDS but was never approved; compounded VIP nasal spray is available under Section 503A through licensed providers.
- Research Stage: Immunomodulatory mechanism well-established in basic science; pulmonary vasodilation studied in controlled trials (aviptadil); neuroprotective properties documented preclinically; broader human RCT evidence for compounded nasal spray is limited
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners
- Prescribing information: View compound reference data on PubChem (CID 53314964)
- How it works: Binds VPAC1 and VPAC2 receptors on immune cells and neurons, suppressing pro-inflammatory cytokines and promoting regulatory immune responses.
- What the research shows: Well-characterized anti-inflammatory mechanism with pulmonary vasodilation confirmed in controlled trials, though clinical evidence for compounded nasal spray remains limited.
What Is VIP?
Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide synthesized endogenously throughout the nervous system and gastrointestinal tract. A 2012 mechanistic review by Harmar and colleagues in the British Journal of Pharmacology (IUPHAR Review 1, covering PAC1, VPAC1, and VPAC2 receptor pharmacology) details how VIP interacts with its target receptors across the CNS, immune system, pancreas, and autonomic neurons. It acts as a neurotransmitter, vasodilator, and immune modulator by binding three G-protein-coupled receptors: VPAC1, VPAC2, and PAC1. VPAC1 and VPAC2 are widely expressed on T cells, macrophages, dendritic cells, and mast cells; receptor activation elevates intracellular cAMP and drives downstream anti-inflammatory signaling.
VIP was first characterized for its vasoactive properties in the 1970s but its immune-regulatory role has become the primary focus of research in recent decades. A 2013 mechanistic review by Delgado and Ganea in Amino Acids (comprehensive review citing 124 references) surveys VIP's anti-inflammatory and immunoregulatory signaling pathways, documenting that VIP at typical in vivo doses of 1–5 nmol (2–15 μg/mouse, i.p.) inhibits TNF, IL-6, and IL-12 production while stimulating IL-10, inhibits NF-κB nuclear translocation, and induces Foxp3+ Tregs through generation of tolerogenic dendritic cells. The review highlights VIP's involvement in vascular, intestinal, and circadian regulation, though the primary focus is its immune-modulatory mechanisms rather than a comprehensive account of all VIP functions. Superpower Health facilitates access to compounded VIP nasal spray through its licensed provider network.
What VIP May Support
1. Immune Modulation and Inflammatory Resolution
VIP's most well-characterized function is its role as an endogenous immune modulator. Unlike conventional anti-inflammatory agents that broadly suppress immune activity, VIP works through receptor-mediated signaling to shift the immune system toward regulatory and anti-inflammatory states. A 2009 review by Smalley and colleagues in Clinical and Experimental Immunology (mechanistic review of VIP's effects on innate immune cells) summarized evidence from in vitro studies using human monocytes, THP1 cells, macrophages, and dendritic cells at VIP concentrations ranging from 10⁻¹⁰ to 10⁻⁶ M, documenting that VIP inhibits LPS-induced TNF-alpha, IL-6, IL-12, and IL-18 production while upregulating the anti-inflammatory cytokine IL-10, characterizing VIP as an immune modulator rather than a simple immune inhibitor. A 2022 mechanistic review by Langer and colleagues in Biomedicines (reviewing 98 references on VIP/PACAP receptor signal transduction, including recent cryo-EM receptor structures) established that VPAC1/VPAC2 activation elevates cAMP through Gαs coupling to adenylate cyclase, which activates PKA and EPAC pathways to suppress NF-κB inflammatory signaling. This mechanism is relevant for individuals with chronic low-grade inflammation, sustained innate immune activation, or immune dysregulation not adequately addressed by standard approaches. Providers may evaluate VIP for individuals whose inflammatory biomarker profiles suggest persistent immune activation not adequately addressed by standard approaches.
2. Pro-Inflammatory Cytokine Suppression
VIP's suppression of pro-inflammatory cytokines is among the best-documented aspects of its biology. A 2015 mechanistic review in Acta Physiologica by Ganea, Hooper, and Kong documented VIP's direct action on immune cells, covering induction of antigen-specific Tregs through generation of tolerogenic dendritic cells (DCVIP) and suppression of Th1/Th17 polarization (with Th17 inhibition observed in vivo but not in vitro). The cytokine profile VIP promotes — elevated IL-10 with suppressed TNF-alpha, IL-6, and IL-12 — represents a shift from inflammatory dominance to immune regulation. This mechanism is distinct from corticosteroid-mediated immunosuppression, which broadly dampens immune function rather than selectively promoting regulatory pathways.
3. Regulatory T Cell Induction and Autoimmune-Relevant Pathways
VIP promotes differentiation of regulatory T cells (Tregs), a cell population that suppresses excessive immune activation and maintains self-tolerance. The same Ganea 2015 review documents that VPAC receptor activation drives Foxp3+ Treg induction and shifts the cytokine environment away from pro-inflammatory Th17 dominance. A 2019 review by Martinez and colleagues in the International Journal of Molecular Sciences (comprehensive review citing 300 references across autoimmune and inflammatory indications) surveyed clinical applications of the VIP axis, reporting that VIP treatment reduced clinical and pathological scores in experimental autoimmune encephalomyelitis models with symptom blockade lasting 60 days, and concluding that VIP represents a biologically plausible target for conditions driven by Th1/Th17 excess and Treg deficiency. The authors noted that the majority of evidence supporting therapeutic benefit remains preclinical, with limited controlled human data across autoimmune indications.
4. Gastrointestinal and Mucosal Immunity
VIP is produced in high concentrations by enteric neurons and acts as a neuromodulator regulating intestinal motility, secretion, and mucosal immune balance. A 2020 review by Sun, Huang, and colleagues in the World Journal of Gastroenterology (narrative review synthesizing preclinical evidence from DSS- and TNBS-induced colitis models in mice) proposed that insufficient VIP levels in the ulcerative colitis intestinal microenvironment accelerate degradation of IL-10 mRNA in regulatory B cells (Bregs), leading to Breg dysfunction and loss of mucosal immune homeostasis. VIP-containing neurons densely innervate the gut mucosa, and a 2019 study by Bains and colleagues in Frontiers in Microbiology using VIP-knockout C57BL/6 mice (N=47 fecal samples across three genotypes) found that VIP deficiency produced significant alterations in gut microbial composition — including net enrichment of Bacteroidetes and Proteobacteria with depletion of Firmicutes (Clostridiales) — reduced Shannon and Chao-1 alpha-diversity indices, and altered Firmicutes-to-Bacteroidetes ratios compared to wild-type and heterozygous littermate controls; the associated increase in intestinal permeability is an indirect finding extrapolated from the microbiota and immune changes reported, rather than the primary endpoint of the study. This is a relevant background mechanism for individuals with concurrent gastrointestinal inflammatory conditions, though clinical trial data on VIP supplementation for gut conditions in humans is limited to observational reports.
5. Neuroprotection and Neuroinflammation
VIP has neuroprotective properties documented in preclinical models. A 2017 review by Deng and Jin in Neurological Research (narrative review of VIP in neurodegenerative disorders) summarized preclinical evidence that VIP inhibits neurodegeneration primarily through indirect glial-mediated mechanisms — promoting neurotrophic factor production and suppressing pro-inflammatory mediators — rather than through direct neuronal action. A 2019 study by Mosley and colleagues in Frontiers in Cellular Neuroscience administered the VIPR2 agonist LBT-3627 (0.06–6.0 mg/kg subcutaneously) in rat Parkinson's disease models (N=5–7 per group, Sprague-Dawley and Lewis strains, using 6-OHDA and alpha-synuclein overexpression) and found that 2.0 mg/kg rescued Treg activity above control levels (p<0.007), reduced reactive microglia by 26–36% at doses of 0.6–6.0 mg/kg, and increased dopaminergic neuron survival by 43% versus vehicle controls (p≤0.05); in the 6-OHDA model, 6.0 mg/kg spared 53% of dopaminergic neurons versus 73% loss in untreated animals. The rationale for intranasal delivery in neuroinflammatory contexts is partly grounded in the hypothesis that nasal-to-brain transport could deliver VIP directly to the CNS. A 2003 preclinical study by Dufes and colleagues in the International Journal of Pharmaceutics using an in situ nasal perfusion technique in rats found that approximately 0.11% of initial radioactivity reached the brain after 30 minutes of intranasal perfusion (using a hypotonic formulation at pH 4 with 0.1% lauroylcarnitine), with intact VIP detected in olfactory bulbs, midbrain, and cerebellum by HPLC, while VIP was completely degraded in the blood compartment. No published human pharmacokinetic studies have confirmed nasal-to-brain VIP transport in humans; this data is preclinical only.
6. Pulmonary Vasodilation (Aviptadil)
VIP's vasodilatory effects have been studied most rigorously in pulmonary hypertension, where synthetic VIP (aviptadil) has been evaluated in controlled trials. A 2008 trial by Leuchte and colleagues in the European Respiratory Journal enrolled N=20 patients with pulmonary hypertension (9 PAH, 8 PH in lung disease, 3 chronic thromboembolic PH) and found that a single inhaled dose of 100 μg aviptadil produced selective pulmonary vasodilation, with 30% of patients (6 of 20) achieving greater than 20% reduction in pulmonary vascular resistance, along with improved stroke volume and increased mixed venous oxygen saturation, without systemic blood pressure changes or side effects. A 2003 prospective intraindividual-controlled trial by Petkov and colleagues in the Journal of Clinical Investigation treated N=8 patients with primary pulmonary hypertension using 200 μg inhaled VIP daily for 24 weeks and found mean pulmonary artery pressure decreased by 13 mmHg (from 59±8 to 46±7 mmHg, p<0.01), pulmonary vascular resistance fell approximately 50% (from 1,009±475 to 586±165 dyne/s/cm⁵), cardiac output increased by 1.7 L/min (from 4.7±2.0 to 6.4±1.6 L/min, p<0.01), and mixed venous oxygen saturation improved from 58±7% to 63±7% (p<0.01). This is the highest-quality controlled evidence for VIP's clinical effects, though it concerns inhaled systemic delivery for a specific cardiovascular indication rather than the nasal spray format used in immune modulation or neuroinflammatory contexts.
VIP vs. Standard Anti-Inflammatory Approaches: Key Differences
VIP is not a general anti-inflammatory; it is an immune modulator that shifts cytokine balance and promotes regulatory immune cell populations rather than suppressing immune function broadly.
Conventional anti-inflammatory medications (NSAIDs, corticosteroids) inhibit specific inflammatory enzymes or suppress broad immune activation. Corticosteroids in particular suppress both the excessive inflammation that causes symptoms and the regulatory immune responses needed for immune homeostasis. A 2007 review by Gonzalez-Rey and Delgado in Trends in Molecular Medicine described a mechanism by which VIP promotes regulatory T cell generation through VPAC receptor signaling and PKA-mediated anti-inflammatory pathways — a selective mechanism distinct from broad immunosuppression; the corticosteroid comparison here is editorial context, not a finding from that review. VIP, by contrast, works through endogenous receptor signaling to upregulate the body's own regulatory mechanisms, as demonstrated by Delgado and colleagues in a 2005 study in the Journal of Leukocyte Biology showing that VIP generates CD4+CD25+Foxp3+ regulatory T cells in vivo in TCR-transgenic mice, with these VIP-induced Tregs suppressing responder T cell proliferation through direct cell contact, preventing delayed-type hypersensitivity reactions, and inhibiting graft-versus-host disease in allogeneic recipients. The distinction is mechanistically significant for conditions where regulatory immune failure rather than excess inflammation is the primary driver.
Head-to-head comparisons between VIP and any specific medication in a controlled trial do not exist. Interpreting VIP's effects as superior or equivalent to any pharmacological agent is not supported by current evidence.
VIP Formulations
VIP is available as a compounded intranasal spray through Superpower's licensed provider network. The intranasal route is used for two pharmacokinetic reasons: first, it avoids first-pass hepatic metabolism that would degrade VIP if administered orally; second, it allows for potential direct access to the central nervous system via olfactory transport, though this has been confirmed only in animal models, not human pharmacokinetic studies.
Intranasal VIP peptide formulations require a preservative vehicle and a delivery device calibrated to deliver consistent microgram doses. The dose per actuation and dosing frequency are determined by the prescribing provider. Bioavailability data for compounded intranasal VIP in humans is limited; systemic absorption via the nasal mucosa occurs, as documented in the Leuchte pulmonary hypertension trials using inhaled aviptadil, but dose-concentration relationships for the compounded nasal spray formulation specifically have not been established in published pharmacokinetic studies.
Intravenous VIP has been studied in pulmonary hypertension research but is not a common delivery route in compounding medicine. Oral VIP is not viable due to peptide degradation in the gastrointestinal tract.
Biomarkers to Monitor With VIP
A licensed provider will determine the appropriate monitoring schedule. Because VIP's mechanism centers on innate immune regulation and inflammatory signaling pathways, the following biomarkers are most relevant before and during use:
- hs-CRP: A sensitive systemic marker of inflammatory activity. Baseline hs-CRP establishes the inflammatory starting point and provides a reference for tracking any response during use. When to test: baseline and at provider-determined intervals.
- TGF-beta-1: A cytokine involved in immune regulation, tissue remodeling, and fibrotic processes. Providers may include TGF-beta-1 in broader inflammatory cytokine panels to assess immune signaling activity. This test is available through specialty laboratory panels; a provider determines whether this marker is relevant to individual clinical assessment.
- TNF-alpha: A pro-inflammatory cytokine directly suppressed by VIP receptor activation. Elevated TNF-alpha at baseline may help identify individuals whose inflammatory profile aligns with VIP's mechanism of action. Specialty testing; provider-determined relevance.
- IL-6: Another pro-inflammatory cytokine downregulated by VIP signaling. Baseline IL-6 can help providers assess the degree of systemic inflammatory activation before and during treatment.
- Complete metabolic panel (CMP): Covers liver and kidney function. Standard safety baseline for any prescription compound. Providers assess at baseline and as clinically indicated.
- CBC (complete blood count): Baseline immune cell populations provide a reference for any shift in white cell counts during use. Given VIP's mechanism of action on T cell populations, baseline lymphocyte count may be informative for providers tracking immune regulatory changes.
For individuals pursuing VIP in the context of chronic inflammation or immune dysregulation, hs-CRP, a complete metabolic panel, and CBC are the standard safety baseline markers. Additional inflammatory cytokine panels (TNF-alpha, IL-6, TGF-beta-1) may be added based on provider assessment. See the guide to immune system biomarkers for broader context on inflammatory and immune testing.
What VIP Is Typically Prescribed For
Providers typically evaluate VIP candidates in the context of documented chronic inflammation with immune dysregulation, or chronic neuroinflammatory conditions where standard anti-inflammatory approaches have been insufficient. VIP may be considered for individuals with chronic low-grade inflammation, persistent innate immune activation, or conditions characterized by Treg deficiency and Th17 excess. The evidence base for these applications is primarily preclinical and mechanistic, with limited controlled human trial data for compounded nasal spray specifically.
VIP is not FDA-approved for any indication. No other uses have been approved by the FDA. The safety and efficacy of VIP for any use have not been established through adequate and well-controlled clinical trials reviewed by the FDA. Any prescribing is the independent clinical judgment of the licensed provider, and candidacy is assessed individually.
Who Should Not Use VIP
A licensed provider will evaluate individual risk factors before prescribing. The following are generally considered contraindications or conditions requiring additional clinical scrutiny:
- Active malignancy: VIP's immunomodulatory and vasodilatory properties have not been studied in cancer populations; potential effects on tumor microenvironment immune regulation and angiogenesis are theoretically uncertain
- Hypotension or hemodynamic instability: VIP is a potent vasodilator; individuals with low baseline blood pressure or conditions associated with hemodynamic fragility may be at risk for symptomatic blood pressure reduction
- Pregnancy and breastfeeding: Safety has not been established in these populations
- Known hypersensitivity to VIP or excipients used in the compounded formulation
- Active, uncontrolled infections: VIP's immune-modulatory effects include partial suppression of pro-inflammatory responses; in the setting of active infection, this mechanism may theoretically impair pathogen clearance
- Concurrent immunosuppressive therapy: The combination of VIP with immunosuppressive medications has not been studied; unpredictable immune interactions are possible
A licensed provider will review current medications, medical history, and individual risk factors before prescribing.
Side Effects and Safety Considerations
The VIP safety profile in compounded nasal spray format is characterized by limited published clinical data. The most rigorous tolerability data comes from inhaled aviptadil in pulmonary hypertension trials, which used a different delivery method and patient population.
Common (reported across VIP delivery forms and observational data):
- Transient nasal irritation or congestion at the application site
- Mild flushing or warmth, consistent with VIP's vasodilatory mechanism
- Transient lightheadedness or dizziness, particularly in individuals with baseline low-normal blood pressure
Less common but reported:
- Symptomatic hypotension: contact your provider if you experience persistent dizziness, syncope, or lightheadedness following dosing
- Gastrointestinal discomfort: nausea or abdominal cramping has been reported in some observational reports, consistent with VIP's enteric regulatory role
- In the pulmonary hypertension trials (inhaled aviptadil), no systemic side effects were observed in the Leuchte 2008 and Petkov 2003 studies; tolerability in these populations was described as excellent
Systematic long-term safety data for compounded intranasal VIP is not available in peer-reviewed literature. Providers typically evaluate tolerability at baseline dosing before escalating to full protocol doses.
Is VIP Legal?
As of April 2026, compounded VIP nasal spray is not FDA-approved for any indication. The synthetic VIP analog aviptadil received FDA Fast Track Designation for COVID-19 ARDS but was denied Breakthrough Therapy Designation and was never approved for any indication. This regulatory history does not apply to compounded VIP nasal spray formulations.
Compounded VIP nasal spray is legal when prescribed by a licensed provider and dispensed by a licensed 503A compounding pharmacy for a patient-specific prescription. The compound is available through Superpower's licensed provider network under this framework. It is not available over the counter.
VIP is an endogenous neuropeptide and is not listed on the 2026 WADA Prohibited List by name. However, WADA maintains broad category language covering peptides that affect tissue repair, immune function, or growth. Athletes subject to anti-doping testing should consult their governing body or a qualified anti-doping advisor before use.
Understanding Your Baseline Before Starting VIP
VIP's mechanism operates primarily through the innate immune system and inflammatory signaling pathways. Baseline testing does not confirm candidacy, but it establishes the inflammatory reference that makes any changes during use measurable. For individuals pursuing VIP for chronic inflammation or immune dysregulation, hs-CRP, CBC, and a complete metabolic panel establish the minimum safety and inflammatory baseline a provider needs to prescribe responsibly. Additional inflammatory cytokine panels may be warranted based on individual clinical presentation. Tracking these markers before, during, and after use is what transforms anecdotal symptom reports into interpretable data.
That approach is central to Superpower's approach to preventive health: objective biomarker data before every clinical decision, and continued tracking through every intervention. Symptom improvement is meaningful. Biomarker data confirms it.
Frequently Asked Questions
What is VIP peptide used for?
VIP (vasoactive intestinal peptide) is an endogenous neuropeptide studied for its immune-modulatory, anti-inflammatory, and neuroprotective properties. It has been studied in pulmonary hypertension (as inhaled aviptadil), and its immunological mechanisms have been investigated in autoimmune and neuroinflammatory research. The compounded nasal spray form is most commonly associated with chronic inflammatory conditions, immune dysregulation, and neuroinflammatory concerns.
Is VIP FDA-approved?
Compounded VIP nasal spray is not FDA-approved for any indication. The synthetic analog aviptadil received Fast Track Designation for COVID-19 ARDS but was never approved for that or any other indication. Compounded VIP can be legally prescribed by a licensed provider and dispensed by a licensed 503A compounding pharmacy for patient-specific use. This is distinct from FDA approval.
What are the side effects of VIP nasal spray?
The most commonly reported effects are transient nasal irritation, mild flushing, and lightheadedness consistent with VIP's vasodilatory mechanism. Symptomatic hypotension is a less common but clinically relevant concern, particularly in individuals with baseline low blood pressure. Systematic safety data for compounded intranasal VIP in human trials is limited; the most rigorous tolerability data comes from inhaled aviptadil in pulmonary hypertension, where the compound was described as well-tolerated without systemic side effects.
How long does VIP take to work?
There is no established timeline based on controlled human trials. Individual response depends on the underlying condition, baseline inflammatory burden, and adherence. A provider will assess response through follow-up biomarker testing at intervals determined by clinical presentation.
Can VIP help with mast cell activation?
VIP receptors are expressed on mast cells, and VPAC receptor activation has been shown to modulate mast cell mediator release in preclinical studies. The cytokine profile shifts VIP promotes (IL-10 upregulation, TNF-alpha suppression) are consistent with the direction of benefit hypothesized in mast cell activation syndrome. Human clinical trial data specifically for VIP in mast cell activation does not exist. Providers working with individuals who have documented mast cell-driven inflammatory patterns may consider VIP as part of a broader evaluation, but this remains an extrapolation from mechanism rather than a trial-supported indication.
Are peptides legal in 2026?
Legality depends on the specific peptide and how it is obtained. Compounded VIP nasal spray is legal when prescribed by a licensed provider and dispensed by a licensed 503A compounding pharmacy. VIP has a USP monograph and is not restricted from compounding under current FDA guidance. It is not available over the counter. Athletes subject to anti-doping testing should consult their governing body before use, as WADA's catch-all peptide categories may apply.
What blood tests should I get before starting VIP?
At minimum, hs-CRP, a complete metabolic panel, and CBC establish the safety baseline and inflammatory reference a provider needs before prescribing. Additional inflammatory cytokine panels (TNF-alpha, IL-6, TGF-beta-1) may be added based on provider assessment. A provider experienced in immune regulation or neuroinflammatory medicine will determine the appropriate scope of pre-treatment testing based on clinical presentation. See the guide to immune system biomarkers for context on the broader landscape of immune and inflammatory testing.
IMPORTANT SAFETY INFORMATION
VIP (vasoactive intestinal peptide) compounded nasal spray is not FDA-approved for any indication. VIP is on the FDA's Category 1 bulk drug substances list and may be legally compounded under Section 503A with a patient-specific prescription. Compounded VIP has not been reviewed by the FDA for safety or efficacy. Superpower is a technology platform; Superpower does not prescribe or dispense medications.
Contraindications: active malignancy; hypotension or hemodynamic instability (VIP is a potent vasodilator); pregnancy and breastfeeding; active uncontrolled infections; concurrent immunosuppressive therapy.
Common side effects: transient nasal irritation, mild flushing or warmth, lightheadedness or dizziness.
Less common: symptomatic hypotension (contact provider if persistent dizziness or syncope); gastrointestinal discomfort.
Long-term safety data for compounded intranasal VIP is not available in peer-reviewed literature.
This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to VIP through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription compound.
Some patients do every standard test and get normal results. Their basic inflammation markers look fine, yet they remain symptomatic in ways conventional medicine struggles to explain. A subset of these individuals may have what researchers describe as dysregulated immune signaling — a sustained inflammatory state that persists beyond what standard markers detect. Understanding what regulates that resolution is where vasoactive intestinal peptide enters the picture.
VIP is an endogenous neuropeptide the body uses to regulate immune homeostasis, vascular tone, and mucosal function. Here is how it works, what the research supports, and how to evaluate whether it may be relevant to your clinical situation.
Key Takeaways
- Regulatory Status: Not FDA-approved for any indication in its compounded nasal spray form. The synthetic VIP analog aviptadil received FDA Fast Track Designation for COVID-19 ARDS but was never approved; compounded VIP nasal spray is available under Section 503A through licensed providers.
- Research Stage: Immunomodulatory mechanism well-established in basic science; pulmonary vasodilation studied in controlled trials (aviptadil); neuroprotective properties documented preclinically; broader human RCT evidence for compounded nasal spray is limited
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners
- Prescribing information: View compound reference data on PubChem (CID 53314964)
- How it works: Binds VPAC1 and VPAC2 receptors on immune cells and neurons, suppressing pro-inflammatory cytokines and promoting regulatory immune responses.
- What the research shows: Well-characterized anti-inflammatory mechanism with pulmonary vasodilation confirmed in controlled trials, though clinical evidence for compounded nasal spray remains limited.
What Is VIP?
Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide synthesized endogenously throughout the nervous system and gastrointestinal tract. A 2012 mechanistic review by Harmar and colleagues in the British Journal of Pharmacology (IUPHAR Review 1, covering PAC1, VPAC1, and VPAC2 receptor pharmacology) details how VIP interacts with its target receptors across the CNS, immune system, pancreas, and autonomic neurons. It acts as a neurotransmitter, vasodilator, and immune modulator by binding three G-protein-coupled receptors: VPAC1, VPAC2, and PAC1. VPAC1 and VPAC2 are widely expressed on T cells, macrophages, dendritic cells, and mast cells; receptor activation elevates intracellular cAMP and drives downstream anti-inflammatory signaling.
VIP was first characterized for its vasoactive properties in the 1970s but its immune-regulatory role has become the primary focus of research in recent decades. A 2013 mechanistic review by Delgado and Ganea in Amino Acids (comprehensive review citing 124 references) surveys VIP's anti-inflammatory and immunoregulatory signaling pathways, documenting that VIP at typical in vivo doses of 1–5 nmol (2–15 μg/mouse, i.p.) inhibits TNF, IL-6, and IL-12 production while stimulating IL-10, inhibits NF-κB nuclear translocation, and induces Foxp3+ Tregs through generation of tolerogenic dendritic cells. The review highlights VIP's involvement in vascular, intestinal, and circadian regulation, though the primary focus is its immune-modulatory mechanisms rather than a comprehensive account of all VIP functions. Superpower Health facilitates access to compounded VIP nasal spray through its licensed provider network.
What VIP May Support
1. Immune Modulation and Inflammatory Resolution
VIP's most well-characterized function is its role as an endogenous immune modulator. Unlike conventional anti-inflammatory agents that broadly suppress immune activity, VIP works through receptor-mediated signaling to shift the immune system toward regulatory and anti-inflammatory states. A 2009 review by Smalley and colleagues in Clinical and Experimental Immunology (mechanistic review of VIP's effects on innate immune cells) summarized evidence from in vitro studies using human monocytes, THP1 cells, macrophages, and dendritic cells at VIP concentrations ranging from 10⁻¹⁰ to 10⁻⁶ M, documenting that VIP inhibits LPS-induced TNF-alpha, IL-6, IL-12, and IL-18 production while upregulating the anti-inflammatory cytokine IL-10, characterizing VIP as an immune modulator rather than a simple immune inhibitor. A 2022 mechanistic review by Langer and colleagues in Biomedicines (reviewing 98 references on VIP/PACAP receptor signal transduction, including recent cryo-EM receptor structures) established that VPAC1/VPAC2 activation elevates cAMP through Gαs coupling to adenylate cyclase, which activates PKA and EPAC pathways to suppress NF-κB inflammatory signaling. This mechanism is relevant for individuals with chronic low-grade inflammation, sustained innate immune activation, or immune dysregulation not adequately addressed by standard approaches. Providers may evaluate VIP for individuals whose inflammatory biomarker profiles suggest persistent immune activation not adequately addressed by standard approaches.
2. Pro-Inflammatory Cytokine Suppression
VIP's suppression of pro-inflammatory cytokines is among the best-documented aspects of its biology. A 2015 mechanistic review in Acta Physiologica by Ganea, Hooper, and Kong documented VIP's direct action on immune cells, covering induction of antigen-specific Tregs through generation of tolerogenic dendritic cells (DCVIP) and suppression of Th1/Th17 polarization (with Th17 inhibition observed in vivo but not in vitro). The cytokine profile VIP promotes — elevated IL-10 with suppressed TNF-alpha, IL-6, and IL-12 — represents a shift from inflammatory dominance to immune regulation. This mechanism is distinct from corticosteroid-mediated immunosuppression, which broadly dampens immune function rather than selectively promoting regulatory pathways.
3. Regulatory T Cell Induction and Autoimmune-Relevant Pathways
VIP promotes differentiation of regulatory T cells (Tregs), a cell population that suppresses excessive immune activation and maintains self-tolerance. The same Ganea 2015 review documents that VPAC receptor activation drives Foxp3+ Treg induction and shifts the cytokine environment away from pro-inflammatory Th17 dominance. A 2019 review by Martinez and colleagues in the International Journal of Molecular Sciences (comprehensive review citing 300 references across autoimmune and inflammatory indications) surveyed clinical applications of the VIP axis, reporting that VIP treatment reduced clinical and pathological scores in experimental autoimmune encephalomyelitis models with symptom blockade lasting 60 days, and concluding that VIP represents a biologically plausible target for conditions driven by Th1/Th17 excess and Treg deficiency. The authors noted that the majority of evidence supporting therapeutic benefit remains preclinical, with limited controlled human data across autoimmune indications.
4. Gastrointestinal and Mucosal Immunity
VIP is produced in high concentrations by enteric neurons and acts as a neuromodulator regulating intestinal motility, secretion, and mucosal immune balance. A 2020 review by Sun, Huang, and colleagues in the World Journal of Gastroenterology (narrative review synthesizing preclinical evidence from DSS- and TNBS-induced colitis models in mice) proposed that insufficient VIP levels in the ulcerative colitis intestinal microenvironment accelerate degradation of IL-10 mRNA in regulatory B cells (Bregs), leading to Breg dysfunction and loss of mucosal immune homeostasis. VIP-containing neurons densely innervate the gut mucosa, and a 2019 study by Bains and colleagues in Frontiers in Microbiology using VIP-knockout C57BL/6 mice (N=47 fecal samples across three genotypes) found that VIP deficiency produced significant alterations in gut microbial composition — including net enrichment of Bacteroidetes and Proteobacteria with depletion of Firmicutes (Clostridiales) — reduced Shannon and Chao-1 alpha-diversity indices, and altered Firmicutes-to-Bacteroidetes ratios compared to wild-type and heterozygous littermate controls; the associated increase in intestinal permeability is an indirect finding extrapolated from the microbiota and immune changes reported, rather than the primary endpoint of the study. This is a relevant background mechanism for individuals with concurrent gastrointestinal inflammatory conditions, though clinical trial data on VIP supplementation for gut conditions in humans is limited to observational reports.
5. Neuroprotection and Neuroinflammation
VIP has neuroprotective properties documented in preclinical models. A 2017 review by Deng and Jin in Neurological Research (narrative review of VIP in neurodegenerative disorders) summarized preclinical evidence that VIP inhibits neurodegeneration primarily through indirect glial-mediated mechanisms — promoting neurotrophic factor production and suppressing pro-inflammatory mediators — rather than through direct neuronal action. A 2019 study by Mosley and colleagues in Frontiers in Cellular Neuroscience administered the VIPR2 agonist LBT-3627 (0.06–6.0 mg/kg subcutaneously) in rat Parkinson's disease models (N=5–7 per group, Sprague-Dawley and Lewis strains, using 6-OHDA and alpha-synuclein overexpression) and found that 2.0 mg/kg rescued Treg activity above control levels (p<0.007), reduced reactive microglia by 26–36% at doses of 0.6–6.0 mg/kg, and increased dopaminergic neuron survival by 43% versus vehicle controls (p≤0.05); in the 6-OHDA model, 6.0 mg/kg spared 53% of dopaminergic neurons versus 73% loss in untreated animals. The rationale for intranasal delivery in neuroinflammatory contexts is partly grounded in the hypothesis that nasal-to-brain transport could deliver VIP directly to the CNS. A 2003 preclinical study by Dufes and colleagues in the International Journal of Pharmaceutics using an in situ nasal perfusion technique in rats found that approximately 0.11% of initial radioactivity reached the brain after 30 minutes of intranasal perfusion (using a hypotonic formulation at pH 4 with 0.1% lauroylcarnitine), with intact VIP detected in olfactory bulbs, midbrain, and cerebellum by HPLC, while VIP was completely degraded in the blood compartment. No published human pharmacokinetic studies have confirmed nasal-to-brain VIP transport in humans; this data is preclinical only.
6. Pulmonary Vasodilation (Aviptadil)
VIP's vasodilatory effects have been studied most rigorously in pulmonary hypertension, where synthetic VIP (aviptadil) has been evaluated in controlled trials. A 2008 trial by Leuchte and colleagues in the European Respiratory Journal enrolled N=20 patients with pulmonary hypertension (9 PAH, 8 PH in lung disease, 3 chronic thromboembolic PH) and found that a single inhaled dose of 100 μg aviptadil produced selective pulmonary vasodilation, with 30% of patients (6 of 20) achieving greater than 20% reduction in pulmonary vascular resistance, along with improved stroke volume and increased mixed venous oxygen saturation, without systemic blood pressure changes or side effects. A 2003 prospective intraindividual-controlled trial by Petkov and colleagues in the Journal of Clinical Investigation treated N=8 patients with primary pulmonary hypertension using 200 μg inhaled VIP daily for 24 weeks and found mean pulmonary artery pressure decreased by 13 mmHg (from 59±8 to 46±7 mmHg, p<0.01), pulmonary vascular resistance fell approximately 50% (from 1,009±475 to 586±165 dyne/s/cm⁵), cardiac output increased by 1.7 L/min (from 4.7±2.0 to 6.4±1.6 L/min, p<0.01), and mixed venous oxygen saturation improved from 58±7% to 63±7% (p<0.01). This is the highest-quality controlled evidence for VIP's clinical effects, though it concerns inhaled systemic delivery for a specific cardiovascular indication rather than the nasal spray format used in immune modulation or neuroinflammatory contexts.
VIP vs. Standard Anti-Inflammatory Approaches: Key Differences
VIP is not a general anti-inflammatory; it is an immune modulator that shifts cytokine balance and promotes regulatory immune cell populations rather than suppressing immune function broadly.
Conventional anti-inflammatory medications (NSAIDs, corticosteroids) inhibit specific inflammatory enzymes or suppress broad immune activation. Corticosteroids in particular suppress both the excessive inflammation that causes symptoms and the regulatory immune responses needed for immune homeostasis. A 2007 review by Gonzalez-Rey and Delgado in Trends in Molecular Medicine described a mechanism by which VIP promotes regulatory T cell generation through VPAC receptor signaling and PKA-mediated anti-inflammatory pathways — a selective mechanism distinct from broad immunosuppression; the corticosteroid comparison here is editorial context, not a finding from that review. VIP, by contrast, works through endogenous receptor signaling to upregulate the body's own regulatory mechanisms, as demonstrated by Delgado and colleagues in a 2005 study in the Journal of Leukocyte Biology showing that VIP generates CD4+CD25+Foxp3+ regulatory T cells in vivo in TCR-transgenic mice, with these VIP-induced Tregs suppressing responder T cell proliferation through direct cell contact, preventing delayed-type hypersensitivity reactions, and inhibiting graft-versus-host disease in allogeneic recipients. The distinction is mechanistically significant for conditions where regulatory immune failure rather than excess inflammation is the primary driver.
Head-to-head comparisons between VIP and any specific medication in a controlled trial do not exist. Interpreting VIP's effects as superior or equivalent to any pharmacological agent is not supported by current evidence.
VIP Formulations
VIP is available as a compounded intranasal spray through Superpower's licensed provider network. The intranasal route is used for two pharmacokinetic reasons: first, it avoids first-pass hepatic metabolism that would degrade VIP if administered orally; second, it allows for potential direct access to the central nervous system via olfactory transport, though this has been confirmed only in animal models, not human pharmacokinetic studies.
Intranasal VIP peptide formulations require a preservative vehicle and a delivery device calibrated to deliver consistent microgram doses. The dose per actuation and dosing frequency are determined by the prescribing provider. Bioavailability data for compounded intranasal VIP in humans is limited; systemic absorption via the nasal mucosa occurs, as documented in the Leuchte pulmonary hypertension trials using inhaled aviptadil, but dose-concentration relationships for the compounded nasal spray formulation specifically have not been established in published pharmacokinetic studies.
Intravenous VIP has been studied in pulmonary hypertension research but is not a common delivery route in compounding medicine. Oral VIP is not viable due to peptide degradation in the gastrointestinal tract.
Biomarkers to Monitor With VIP
A licensed provider will determine the appropriate monitoring schedule. Because VIP's mechanism centers on innate immune regulation and inflammatory signaling pathways, the following biomarkers are most relevant before and during use:
- hs-CRP: A sensitive systemic marker of inflammatory activity. Baseline hs-CRP establishes the inflammatory starting point and provides a reference for tracking any response during use. When to test: baseline and at provider-determined intervals.
- TGF-beta-1: A cytokine involved in immune regulation, tissue remodeling, and fibrotic processes. Providers may include TGF-beta-1 in broader inflammatory cytokine panels to assess immune signaling activity. This test is available through specialty laboratory panels; a provider determines whether this marker is relevant to individual clinical assessment.
- TNF-alpha: A pro-inflammatory cytokine directly suppressed by VIP receptor activation. Elevated TNF-alpha at baseline may help identify individuals whose inflammatory profile aligns with VIP's mechanism of action. Specialty testing; provider-determined relevance.
- IL-6: Another pro-inflammatory cytokine downregulated by VIP signaling. Baseline IL-6 can help providers assess the degree of systemic inflammatory activation before and during treatment.
- Complete metabolic panel (CMP): Covers liver and kidney function. Standard safety baseline for any prescription compound. Providers assess at baseline and as clinically indicated.
- CBC (complete blood count): Baseline immune cell populations provide a reference for any shift in white cell counts during use. Given VIP's mechanism of action on T cell populations, baseline lymphocyte count may be informative for providers tracking immune regulatory changes.
For individuals pursuing VIP in the context of chronic inflammation or immune dysregulation, hs-CRP, a complete metabolic panel, and CBC are the standard safety baseline markers. Additional inflammatory cytokine panels (TNF-alpha, IL-6, TGF-beta-1) may be added based on provider assessment. See the guide to immune system biomarkers for broader context on inflammatory and immune testing.
What VIP Is Typically Prescribed For
Providers typically evaluate VIP candidates in the context of documented chronic inflammation with immune dysregulation, or chronic neuroinflammatory conditions where standard anti-inflammatory approaches have been insufficient. VIP may be considered for individuals with chronic low-grade inflammation, persistent innate immune activation, or conditions characterized by Treg deficiency and Th17 excess. The evidence base for these applications is primarily preclinical and mechanistic, with limited controlled human trial data for compounded nasal spray specifically.
VIP is not FDA-approved for any indication. No other uses have been approved by the FDA. The safety and efficacy of VIP for any use have not been established through adequate and well-controlled clinical trials reviewed by the FDA. Any prescribing is the independent clinical judgment of the licensed provider, and candidacy is assessed individually.
Who Should Not Use VIP
A licensed provider will evaluate individual risk factors before prescribing. The following are generally considered contraindications or conditions requiring additional clinical scrutiny:
- Active malignancy: VIP's immunomodulatory and vasodilatory properties have not been studied in cancer populations; potential effects on tumor microenvironment immune regulation and angiogenesis are theoretically uncertain
- Hypotension or hemodynamic instability: VIP is a potent vasodilator; individuals with low baseline blood pressure or conditions associated with hemodynamic fragility may be at risk for symptomatic blood pressure reduction
- Pregnancy and breastfeeding: Safety has not been established in these populations
- Known hypersensitivity to VIP or excipients used in the compounded formulation
- Active, uncontrolled infections: VIP's immune-modulatory effects include partial suppression of pro-inflammatory responses; in the setting of active infection, this mechanism may theoretically impair pathogen clearance
- Concurrent immunosuppressive therapy: The combination of VIP with immunosuppressive medications has not been studied; unpredictable immune interactions are possible
A licensed provider will review current medications, medical history, and individual risk factors before prescribing.
Side Effects and Safety Considerations
The VIP safety profile in compounded nasal spray format is characterized by limited published clinical data. The most rigorous tolerability data comes from inhaled aviptadil in pulmonary hypertension trials, which used a different delivery method and patient population.
Common (reported across VIP delivery forms and observational data):
- Transient nasal irritation or congestion at the application site
- Mild flushing or warmth, consistent with VIP's vasodilatory mechanism
- Transient lightheadedness or dizziness, particularly in individuals with baseline low-normal blood pressure
Less common but reported:
- Symptomatic hypotension: contact your provider if you experience persistent dizziness, syncope, or lightheadedness following dosing
- Gastrointestinal discomfort: nausea or abdominal cramping has been reported in some observational reports, consistent with VIP's enteric regulatory role
- In the pulmonary hypertension trials (inhaled aviptadil), no systemic side effects were observed in the Leuchte 2008 and Petkov 2003 studies; tolerability in these populations was described as excellent
Systematic long-term safety data for compounded intranasal VIP is not available in peer-reviewed literature. Providers typically evaluate tolerability at baseline dosing before escalating to full protocol doses.
Is VIP Legal?
As of April 2026, compounded VIP nasal spray is not FDA-approved for any indication. The synthetic VIP analog aviptadil received FDA Fast Track Designation for COVID-19 ARDS but was denied Breakthrough Therapy Designation and was never approved for any indication. This regulatory history does not apply to compounded VIP nasal spray formulations.
Compounded VIP nasal spray is legal when prescribed by a licensed provider and dispensed by a licensed 503A compounding pharmacy for a patient-specific prescription. The compound is available through Superpower's licensed provider network under this framework. It is not available over the counter.
VIP is an endogenous neuropeptide and is not listed on the 2026 WADA Prohibited List by name. However, WADA maintains broad category language covering peptides that affect tissue repair, immune function, or growth. Athletes subject to anti-doping testing should consult their governing body or a qualified anti-doping advisor before use.
Understanding Your Baseline Before Starting VIP
VIP's mechanism operates primarily through the innate immune system and inflammatory signaling pathways. Baseline testing does not confirm candidacy, but it establishes the inflammatory reference that makes any changes during use measurable. For individuals pursuing VIP for chronic inflammation or immune dysregulation, hs-CRP, CBC, and a complete metabolic panel establish the minimum safety and inflammatory baseline a provider needs to prescribe responsibly. Additional inflammatory cytokine panels may be warranted based on individual clinical presentation. Tracking these markers before, during, and after use is what transforms anecdotal symptom reports into interpretable data.
That approach is central to Superpower's approach to preventive health: objective biomarker data before every clinical decision, and continued tracking through every intervention. Symptom improvement is meaningful. Biomarker data confirms it.
Frequently Asked Questions
What is VIP peptide used for?
VIP (vasoactive intestinal peptide) is an endogenous neuropeptide studied for its immune-modulatory, anti-inflammatory, and neuroprotective properties. It has been studied in pulmonary hypertension (as inhaled aviptadil), and its immunological mechanisms have been investigated in autoimmune and neuroinflammatory research. The compounded nasal spray form is most commonly associated with chronic inflammatory conditions, immune dysregulation, and neuroinflammatory concerns.
Is VIP FDA-approved?
Compounded VIP nasal spray is not FDA-approved for any indication. The synthetic analog aviptadil received Fast Track Designation for COVID-19 ARDS but was never approved for that or any other indication. Compounded VIP can be legally prescribed by a licensed provider and dispensed by a licensed 503A compounding pharmacy for patient-specific use. This is distinct from FDA approval.
What are the side effects of VIP nasal spray?
The most commonly reported effects are transient nasal irritation, mild flushing, and lightheadedness consistent with VIP's vasodilatory mechanism. Symptomatic hypotension is a less common but clinically relevant concern, particularly in individuals with baseline low blood pressure. Systematic safety data for compounded intranasal VIP in human trials is limited; the most rigorous tolerability data comes from inhaled aviptadil in pulmonary hypertension, where the compound was described as well-tolerated without systemic side effects.
How long does VIP take to work?
There is no established timeline based on controlled human trials. Individual response depends on the underlying condition, baseline inflammatory burden, and adherence. A provider will assess response through follow-up biomarker testing at intervals determined by clinical presentation.
Can VIP help with mast cell activation?
VIP receptors are expressed on mast cells, and VPAC receptor activation has been shown to modulate mast cell mediator release in preclinical studies. The cytokine profile shifts VIP promotes (IL-10 upregulation, TNF-alpha suppression) are consistent with the direction of benefit hypothesized in mast cell activation syndrome. Human clinical trial data specifically for VIP in mast cell activation does not exist. Providers working with individuals who have documented mast cell-driven inflammatory patterns may consider VIP as part of a broader evaluation, but this remains an extrapolation from mechanism rather than a trial-supported indication.
Are peptides legal in 2026?
Legality depends on the specific peptide and how it is obtained. Compounded VIP nasal spray is legal when prescribed by a licensed provider and dispensed by a licensed 503A compounding pharmacy. VIP has a USP monograph and is not restricted from compounding under current FDA guidance. It is not available over the counter. Athletes subject to anti-doping testing should consult their governing body before use, as WADA's catch-all peptide categories may apply.
What blood tests should I get before starting VIP?
At minimum, hs-CRP, a complete metabolic panel, and CBC establish the safety baseline and inflammatory reference a provider needs before prescribing. Additional inflammatory cytokine panels (TNF-alpha, IL-6, TGF-beta-1) may be added based on provider assessment. A provider experienced in immune regulation or neuroinflammatory medicine will determine the appropriate scope of pre-treatment testing based on clinical presentation. See the guide to immune system biomarkers for context on the broader landscape of immune and inflammatory testing.
IMPORTANT SAFETY INFORMATION
VIP (vasoactive intestinal peptide) compounded nasal spray is not FDA-approved for any indication. VIP is on the FDA's Category 1 bulk drug substances list and may be legally compounded under Section 503A with a patient-specific prescription. Compounded VIP has not been reviewed by the FDA for safety or efficacy. Superpower is a technology platform; Superpower does not prescribe or dispense medications.
Contraindications: active malignancy; hypotension or hemodynamic instability (VIP is a potent vasodilator); pregnancy and breastfeeding; active uncontrolled infections; concurrent immunosuppressive therapy.
Common side effects: transient nasal irritation, mild flushing or warmth, lightheadedness or dizziness.
Less common: symptomatic hypotension (contact provider if persistent dizziness or syncope); gastrointestinal discomfort.
Long-term safety data for compounded intranasal VIP is not available in peer-reviewed literature.
.avif)
.avif)
.avif)
.avif)
.avif)
.jpg)
.avif)
